Memantine Sandoz
Memantine Sandoz helps improve memory and nerve signals for people with moderate to severe Alzheimer's disease.
Form
tabletti, kalvopäällysteinen
Strength
10 mg
Active Ingredient
Memantine hydrochloride
Manufacturer
Sandoz A/S
How to Use
Dosage
The starting dose is gradually increased over four weeks. From week 4 onwards, the recommended dose for adults and elderly patients is 20 mg once a day.
Method
Take this medicine by mouth once a day, with or without food. Swallow the tablet whole with some water. Take it regularly at the same time each day.
Important
The maximum daily dose for adults and elderly patients is 20 mg.
Possible Side Effects
COMMON
- •Headache
- •Drowsiness
- •Constipation
- •Elevated liver enzyme values
- •Dizziness
- •Balance disorders
- •Shortness of breath
- •High blood pressure
- •Drug hypersensitivity
RARE
- •Fatigue
- •Fungal infections
- •Confusion
- •Hallucinations
- •Vomiting
- •Abnormal gait
- •Heart failure
- •Blood clot in veins (thrombosis/thromboembolism)
- •Epileptic seizures
- •Pancreatitis
- •Liver inflammation (hepatitis)
- •Psychotic reactions
Important Warnings
- Do not take if you are allergic to memantine hydrochloride or any other ingredients in this medicine.
- Talk to your doctor if you have ever had epileptic seizures.
- Talk to your doctor if you recently had a heart attack, have heart failure, or uncontrolled high blood pressure.
- If you have kidney problems, your doctor will monitor your kidney function and may adjust your dose.
- Avoid taking this medicine with amantadine, ketamine, dextromethorphan, or other NMDA antagonists.
Show 3 more warnings
- Do not use Memantine Sandoz if you are pregnant or planning to become pregnant.
- Do not breastfeed if you are taking Memantine Sandoz.
- This medicine may affect your reaction time, making it unsafe to drive or operate machinery.
Use in Elderly Patients
Category C
Suitable for older adults, with specific precautions. Reduce the dose in severe renal impairment. Consider potential significant interactions. (updated 18.3.2024)